A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
700 patients around the world
Available in Argentina, Mexico, United States, Colombia, Spain
Bristol-Myers Squibb
20Research sites
700Patients around the world
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Instituto Médico de Alta Complejidad San Isidro IMACSI